全文获取类型
收费全文 | 66998篇 |
免费 | 5924篇 |
国内免费 | 75篇 |
学科分类
医药卫生 | 72997篇 |
出版年
2023年 | 397篇 |
2021年 | 1401篇 |
2020年 | 903篇 |
2019年 | 1455篇 |
2018年 | 1552篇 |
2017年 | 1234篇 |
2016年 | 1282篇 |
2015年 | 1401篇 |
2014年 | 1847篇 |
2013年 | 2734篇 |
2012年 | 3984篇 |
2011年 | 4018篇 |
2010年 | 2173篇 |
2009年 | 1850篇 |
2008年 | 3304篇 |
2007年 | 3424篇 |
2006年 | 3315篇 |
2005年 | 3087篇 |
2004年 | 2875篇 |
2003年 | 2558篇 |
2002年 | 2479篇 |
2001年 | 1621篇 |
2000年 | 1637篇 |
1999年 | 1460篇 |
1998年 | 616篇 |
1997年 | 502篇 |
1996年 | 467篇 |
1995年 | 502篇 |
1994年 | 430篇 |
1993年 | 388篇 |
1992年 | 1178篇 |
1991年 | 1186篇 |
1990年 | 1115篇 |
1989年 | 1098篇 |
1988年 | 913篇 |
1987年 | 1040篇 |
1986年 | 965篇 |
1985年 | 983篇 |
1984年 | 780篇 |
1983年 | 635篇 |
1982年 | 418篇 |
1981年 | 399篇 |
1979年 | 705篇 |
1978年 | 531篇 |
1977年 | 448篇 |
1976年 | 457篇 |
1975年 | 400篇 |
1974年 | 523篇 |
1973年 | 458篇 |
1972年 | 388篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
Greer Hunter R. Miller Kristen Samay Sadaf Nellan Anandani Green Adam L. 《Journal of neuro-oncology》2022,159(2):301-308
Journal of Neuro-Oncology - The role of white blood cells (WBC) in the pediatric central nervous system (CNS) tumor microenvironment is incompletely defined. We hypothesized that the WBC profile in... 相似文献
4.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
5.
6.
Alexander D. Sherry MD Kelsey L. Corrigan MD MPH Ramez Kouzy MD Joseph Abi Jaoude MD Yumeng Yang MS Roshal R. Patel MD Douglas J. Totten MD MBA Neil B. Newman MD MS Prajnan Das MD MS MPH Cullen Taniguchi MD PhD Bruce Minsky MD Rebecca A. Snyder MD MPH C. David Fuller MD PhD Ethan Ludmir MD 《Cancer》2023,129(21):3430-3438
7.
8.
ChiaChi Lin TsaiSheng Yang ChiaJui Yen Rebecca Cheng Junjun Liu Chiun Hsu 《The oncologist》2020,25(12)
Lessons Learned
- The combination of ramucirumab (8 mg/kg intravenous, day 1 every 2 weeks) and FOLFOX4 as first‐line treatment in patients with advanced hepatocellular carcinoma (HCC) was not sufficiently tolerated.
- Preliminary efficacy data suggest that the combination may provide clinical benefit to patients with HCC.
- Dose modification and patient selection should be considered for the future development of ramucirumab plus FOLFOX chemotherapy for advanced HCC.
9.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
10.
Patel Mallika P. Kirkpatrick John P. Johnson Margaret O. Healy Patrick Herndon James E. Lipp Eric S. Miller Elizabeth S. Desjardins Annick Randazzo Dina Friedman Henry S. Ashley David M. Peters Katherine B. 《Journal of neuro-oncology》2020,147(2):477-483
Journal of Neuro-Oncology - Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin’s lymphoma that involves the brain, spinal cord, or leptomeninges, without evidence of... 相似文献